Madrid, May 20th, 2008—Cellerix, a biopharmaceutical company that develops and produces innovative medicines based on cell therapy, has appointed Guillermo Sellers as the new Medical and Regulatory Vice President of its management team.

Guillermo Sellers is Doctor of Medicine and Surgery and holds a Masters in General Management (IESE). In 1988, Sellers and other partners founded the first CRO, or Clinical Research Organisation in Spain, the CIBEST (Centro de Investigación y Bioestadística). After selling the CRO to the Swiss multinational SGS (Societé General de Surveillance), Guillermo held the post of Assistant Director General and Director of the Business Development Unit. In 2003, Sellers joined Serono (currently Merck Serono) as the Medical Director for Spain and Portugal, where he was in charge of research and providing support for marketing and sales activities in these two countries.

In addition to his more than 20 years of professional experience, Guillermo Sellers is the author of numerous publications and scientific articles in national and international magazines, as well as of several specialised books.

Eduardo Bravo, Chief Executive of Cellerix, has underscored the importance of Guillermo Seller's appointment. "Cellerix is at a key moment in its development, with various products in the clinical phase, two of which are on the verge of preparing registration dossiers. Guillermo's experience provides Cellerix with an important underpinning for its strategic area," Bravo says. In his new post, Sellers will be responsible for the Department of Clinical Operations and for the Department of Regulatory Affairs, as well as for the Medical Department.

Note to editors.

Cellerix is a biopharmaceutical company developing innovative medicines based on cell therapy. The company has two products undergoing clinical trials: Ontaril (Cx401) for the treatment of perianal fistulas, currently in Phase III, and Cx501 for skin regeneration, currently in Phase II. Ontaril and Cx501 have been designated orphan status by the European Medicines Agency (EMEA). Cellerix completed in September 2007 a €27.2 million financing round led by international venture capital companies. In October 2007 it entered into an exclusive license and development agreement with Axcan Pharma for the North American rights to Cx401.